Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review.

Oncol Res · 2026 · PMC13220099 · PMID 42220439

Europe PMC DOI

hedged sentence

0.2840

closest p · 5.7× alpha

0.2840

boldest claim

The sentences

did not reach statistical significancep = 0.284not close (p > 0.1)

Although OS did not reach statistical significance (HR = 0.903, p = 0.284), fewer death events occurred in the abemaciclib group (208 vs. 234), hinting at an emerging survival benefit [ 31 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.